Alzheimer’s Disease Therapeutics and Diagnostics Market Outlook 2022-2028

1
Alzheimers Disease Therapeutics and Diagnostics
Market Outlook 2022- 2028
Triton Market Research presents the Global
Alzheimers Disease Therapeutics and Diagnostics
Market report segmented by Therapeutics (Disease
Stage Prodromal Stage, Early/Middle Stage Mild
To Moderate AD, Late Stage Severe AD, Drug Type
Marketed Drugs, Pipeline Drugs, Generic
Branded Branded, Generic), by Diagnostics
(Magnetic Resonance Imaging, Positron Emission
Tomography, Blood Test, Computed Tomography,
Electroencephalography, Lumbar Puncture Test,
Other Diagnostics), by Geographical Region (North
America, Europe, Asia-Pacific, Latin America,
Middle East and Africa), discussing Market
Summary, Industry Outlook, Market Drivers, Market
Challenges, Market Opportunities, Competitive
Landscape, Research Methodology Scope, and
Global Market Size, Forecasts, Analysis
(2022-2028). Triton Market Researchs report has
put forth that the Global Alzheimers Disease
Therapeutics and Diagnostics Market is likely to
evolve at a CAGR of 6.98 over the estimated
duration 2022-2028.
Request Free sample https//www.tritonmarketresea
rch.com/reports/alzheimers-disease-therapeutics-an
d-diagnostic- marketrequest-free-sample
2
According to United Nations World Population
Prospects 2019, 1 in every 6 people in the world
will be above the age of 65 years by 2050. Due to
aging, people in this age group are more prone to
developing neurological conditions. The
year-over-year expanding aging populace is
expected to increase the prevalence of
Alzheimers disease, and, consequently, boost the
demand for therapeutics and diagnostics. Regulatio
ns set by the US Food and Drug Administration
require any company intending to manufacture a
new drug to seek approval from the regulatory
body prior to conducting clinical trials in the
country. Regulations pertaining to drug
development and commercialization negatively
affect the market growth. North America dominated
the global market in 2021 with the highest share,
and is anticipated to continue this dominance
until the end of the forecasted period. An
increasing aging populace, the presence of
leading market players, and increased investments
in research development have substantially
enhanced the demand for therapeutics and
diagnostics in the region. This, in turn, is
driving the market growth in North America. Merck
and Co, Johnson and Johnson, Eli Lilly Company,
Allergan Plc (acquired by Abbvie), Zydus Cadila,
GE Healthcare, Eisai Co Ltd, Baxter International
Inc, Siemens Healthineers AG, Novartis AG,
Pfizer Inc, F. Hoffmann-La Roche AG, Teva
Pharmaceutical Industries Ltd, Amarantus
Bioscience Holdings Inc, Lupin Limited, Cognoptix
Inc, Sun Pharmaceuticals Industries Ltd, and
Biogen Inc are some of the eminent players in the
market. Although many alternative therapies for
AD diagnosis and treatment are not available, the
introduction of generic drugs and novel
diagnostic methodologies has led to increased
internal substitution. And with the introduction
of these drugs, the competition among market
players for developing new treatment and
diagnostics methodologies has increased
significantly. Besides, the industry is also
witnessing meaningful strategic partnerships. A
high disease burden and the lack of
disease-modifying therapies also present
opportunities for novel products. Contact Us
sales_at_tritonmarketresearch.com Phone 44 7441
911839